34077 Efficacy of oral sarecycline in Hispanics with facial inflammatory acne

Abstract

In 2019, 60.6 million in the U.S. were Hispanics, with acne affecting 32% of Hispanic women. Sarecycline is a narrow-spectrum, third-generation tetracycline-class antibiotic, FDA approved for the treatment of moderate-to-severe acne in patients aged 9 and older. With increasing focus on outcomes in skin of color, we report pooled post hoc analysis of efficacy and safety data on sarecycline in Hispanics from pivotal phase 3, multicenter, randomized, double-blind, placebo-controlled studies SC1401 and SC1402.